top of page

BLOG POSTS

IMPORTANT MESSAGES FROM NBR

Search

Cerevel Therapeutics Announces Positive Results in Emraclidine Ambulatory Blood Pressure Monitoring

Cerevel Therapeutics Announces Positive Results in Emraclidine Ambulatory Blood Pressure Monitoring

Cerevel Therapeutics Announces Positive Results in Emraclidine Ambulatory Blood Pressure Monitoring

Data provide clear evidence that emraclidine does not induce an increase in blood pressure with chronic dosing in people living with...

Neuro-Behavioral Clinical Research

Dec 19, 20225 min read

Fanapt® Shown to be Effective in Bipolar I Disorder in Phase III Clinical Study

Fanapt® Shown to be Effective in Bipolar I Disorder in Phase III Clinical Study

Fanapt® Shown to be Effective in Bipolar I Disorder in Phase III Clinical Study

Supplemental New Drug Application (sNDA) planned for 2023 WASHINGTON, Dec. 19, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda)...

Neuro-Behavioral Clinical Research

Dec 19, 20226 min read

Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone

Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone

Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone

At the Day 15 primary endpoint, zuranolone 50 mg showed a statistically significant and clinically meaningful reduction in depressive...

Neuro-Behavioral Clinical Research

Jun 14, 202112 min read

VIDEOS

VALUABLE RESOURCES FROM NBR

bottom of page